Please login to the form below

Not currently logged in
Email:
Password:

Apitope strengthens its board with new director

Dr William Jenkins joins the board following a 30-year career in clinical medicine

Dr William JenkinsClinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.

He has also served on several boards including Ablynx, Evotec and Acambis.

Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.

“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.

“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”

22nd March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics